Cargando…
Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells
Inhibition of Brd4 by JQ1 treatment showed potential in the treatment of glioma, however, some cases showed low sensitivity of JQ1. In addition, the pre-clinical analysis showed its limitation by demonstrating that transient treatment with JQ1 leads to aggressive tumor development. Thus, an improved...
Autores principales: | Han, Liping, Zhao, Qingwei, Liang, Xianhong, Wang, Xiaoqing, Zhang, Zhen, Ma, Zhiguo, Zhao, Miaoqing, Wang, Aihua, Liu, Shuai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542215/ https://www.ncbi.nlm.nih.gov/pubmed/28484091 http://dx.doi.org/10.18632/oncotarget.17314 |
Ejemplares similares
-
Autophagy flux inhibition, G2/M cell cycle arrest and apoptosis induction by ubenimex in glioma cell lines
por: Han, Liping, et al.
Publicado: (2017) -
Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer
por: Chen, Ruichuan, et al.
Publicado: (2014) -
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
por: Liu, Shuai, et al.
Publicado: (2016) -
Ubenimex, an APN inhibitor, could serve as an anti-tumor drug in RT112 and 5637 cells by operating in an Akt-associated manner
por: Wang, Xiaoqing, et al.
Publicado: (2018) -
Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway
por: Wang, Yanjun, et al.
Publicado: (2019)